|
ZNF167 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.44249065417534E-15 |
| Normal-vs-Stage2 |
9.22190102059517E-11 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.11022302462516E-15 |
| Stage1-vs-Stage2 |
3.616200E-01 |
| Stage1-vs-Stage3 |
1.057480E-03 |
| Stage1-vs-Stage4 |
4.010600E-04 |
| Stage2-vs-Stage3 |
1.394830E-01 |
| Stage2-vs-Stage4 |
2.234100E-02 |
| Stage3-vs-Stage4 |
3.107200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.98239999999106E-06 |
| Normal-vs-Asian |
2.54109999997532E-06 |
| Caucasian-vs-AfricanAmerican |
7.374200E-01 |
| Caucasian-vs-Asian |
5.736800E-03 |
| AfricanAmerican-vs-Asian |
2.562400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.00597308261285E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
1.958390E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62569957495862E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62625468647093E-12 |
| Normal-vs-Age(81-100Yrs) |
1.399990E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.718600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.943550E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.538800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.667390E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.067800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.935200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.30250032981394E-10 |
| Classical-VS-Follicular |
9.218800E-01 |
| Classical-VS-Other |
5.707400E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
5.79349999973999E-07 |
| Tall-VS-Other |
9.601900E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
4.681000E-01 |
| Follicular-VS-Normal |
2.7745028496895E-11 |
| Other-VS-Normal |
2.431800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.63122856836162E-14 |
| Normal-vs-N1 |
6.17228490540356E-12 |
| N0-vs-N1 |
2.331600E-01 |
|
|
